Covid evolution wipes out another antibody treatment; Stanford investigates president over research misconduct allegations

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by     Covid evolution wipes out another antibody treatment, threatening the country's medicine cabinet By Andrew Joseph Kristoffer Tripplaar/AP The rapid evolution of the SARS-CoV-2 virus had already knocked out several other monoclonal antibodies for the treatment of Covid.  Read More STAT+: On the long road to treating Huntington's genetic stutter, scientists return to overlooked clues By Megan Molteni Mike Reddy for STAT An observation made 25 years ago — and then ignored by most of the Huntington’s field — may hold the answer to a possible treatment. Read More Stanford is investigating its president over allegations of research misconduct By Andrew Joseph Cindy Ord/Getty Images for World Science Festival Stanford is investigating its president Marc Tessier-Lavigne over allegations that papers on which he is a co-author include altered images. Read More Sponsored Insight by STAT TRIALS PULSE Could warning signs in Summit Therapeutics' clinical trial activity have hinted at bad results months before they were announced? There are an average of over 6,800 clinical trials updates every day. Trying to analyze these changes and identify patterns is a staggering but essential undertaking for life sciences professionals seeking competitive intelligence. That's where STAT Trials Pulse steps in. We connect disparate sources of clinical trials data, detect important updates, and add context to deliver a curated stream of actionable alerts. Learn more at statnews.com/trials-pulse, or start your 30-day free trial. CDC launches initiative to test wastewater for polioviruses in some communities By Helen Branswell Emory University/CDC via AP The launch of the initiative follows the discovery of vaccine-derived polioviruses circulating in the sewage in and around New York City. Read More Wednesday, November 30, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser

To treat Huntington’s, scientists return to overlooked clues; Stanford investigating president over alleged research misconduct

An observation made 25 years ago — and then ignored by most of the Huntington's field — may hold the answer to a possible treatment. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by   STAT+: On the long road to treating Huntington's genetic stutter, scientists return to overlooked clues By Megan Molteni Mike Reddy for STAT An observation made 25 years ago — and then ignored by most of the Huntington’s field — may hold the answer to a possible treatment. Read More Stanford is investigating its president over allegations of research misconduct By Andrew Joseph Cindy Ord/Getty Images for World Science Festival Stanford is investigating its president Marc Tessier-Lavigne over allegations that papers on which he is a co-author include altered images. Read More CDC launches initiative to test wastewater for polioviruses in some communities By Helen Branswell Emory University/CDC via AP The launch of the initiative follows the discovery of vaccine-derived polioviruses circulating in the sewage in and around New York City. Read More Sponsored Insight by Sanofi Chasing the miracles of science to ease the burden for people living with multiple myeloma Doubling down on next generation approaches and therapies has contributed to durable survival gains for those living with multiple myeloma, but there is still work to be done. Every year, more than 130,000 people worldwide still receive the life-altering diagnosis of multiple myeloma. Learn more about the latest in multiple myeloma in our Q&A with Sanofi's Global Head of Oncology Development & Pediatric Innovation, Peter Adamson. With no exit strategy from 'zero Covid' policy, China could face tsunami in cases, experts fear By Helen Branswell Kevin Frayer/Getty The zero Covid policy seems doomed to fail in the face of the highly transmissible Omicron variant of the SARS-CoV-2 virus, experts say. Read More 'The more voice, the better': How tech could bring a fuller picture of living with a disability to health records By Jayne Williamson-Lee Wikimedia Commons STAT spoke with University of Pittsburgh physician Amy Houtrow about the intersection of health technology and disability. Read More Opinion: Better lab test standards can ensure precision medicine is truly precise By Jeff Allen and Lisa Lacasse SAUL LOEB/AFP/Getty Images The oversight of lab tests for targeted cancer therapies and other treatments has not kept pace with innovation. Read More Wednesday, November 30, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser

Get 50% off six months of STAT+

Cut through the noise with the most trusted newsroom in the life sciences. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

www.statnews.com/stat-plus Stay in the know with STAT+ When you subscribe at 50% off for six months, here’s what you get: Unlimited article access Get unlimited access to our entire archive of articles — nearly seven years of the best stories of scientific discovery with no limitations. Award-winning journalism Our newsroom is comprised of some of the nation's most trusted and well-connected health care, business, and financial journalists. Subscriber-only newsletters Sent every weekday, our two STAT+ newsletters deliver exclusive, in-depth reporting on the latest trends and ground breaking discoveries. Exclusive events Expect regular invitations to online and in-person subscriber networking events, webinars, and discounts to our STAT Summits. Premium data tools Get access to data trackers, dashboards, and tools that allow you to study your competitors and track your industry more closely. Subscribe now Offer valid through Dec. 5 Wednesday, November 30, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT Plus promotional emails Contact Us

New Nvidia tools streamline AI adoption process for hospitals

The latest stories trending on MedCity News.

Not rendering correctly? View this email as a web page here. TOP STORIES Nvidia Aims to Simplify AI Adoption Process for Cincinnati Children's, UCSF Nvidia unveiled new tools designed to make it easier for hospitals to integrate AI models related to medical imaging into their clinical workflows. The tools have been adopted by major cloud infrastructure providers, as well as healthcare providers and AI software companies. Some of these include Cincinnati Children's Hospital, University of California San Francisco, England's National Health Service and Qure.ai. Sponsored Content What Does It Really Mean To Deliver 'Whole-person Care'? From Thyme Care "Whole-person care" is a term that gets thrown around a lot today, as a kind of virtue signaling for more personalized forms of care. But true whole-person care is not a buzzword; it's a complex delivery model that engages an integrated multidisciplinary team on the patient's behalf. At Thyme Care, we believe that's the future of oncology care – but to get there, healthcare organizations must understand what whole-person care and a team-based approach really mean.  Are You Coming to the Premier National Healthcare Investing Conference? Don't miss out on your chance to save $800 and join us for exclusive networking opportunities and engaging content that highlights the opportunities and challenges the industry faces as it continues to evolve. INVEST 2023 will unite innovative startups, active investors as well as forward-thinking healthcare providers, payers and life science companies. Ex-hospital CEO Sues MetroHealth for Alleged Illegal Firing By Amanda James Tuesday, November 29, 2022 9:32 PM Dr. Akram Boutros said in a lawsuit filed Monday in Cuyahoga County court that Cleveland-based MetroHealth's board of directors violated open meeting laws when it "secretly hired" counsel to investigate him and then terminated him without mandatory public notice.  Read more » AstraZeneca Puts Up $200M in Solid Bet on Startup's Take on Cancer Cell Therapy By Frank Vinluan Tuesday, November 29, 2022 5:57 PM AstraZeneca is jumping into the chase for cell therapies that address solid tumors by acquiring Neogene Therapeutics. The startup's technology can be used to discover and develop novel targets that may be able to broaden the scope of cell therapies for cancer. Read more » Nvidia Aims to Simplify AI Adoption Process for Cincinnati Children's, UCSF By Katie Adams Tuesday, November 29, 2022 5:40 PM Nvidia unveiled new tools designed to make it easier for hospitals to integrate AI models related to medical imaging into their clinical workflows. The tools have been adopted by major cloud infrastructure providers, as well as healthcare providers and AI software companies. Some of these include Cincinnati Children's Hospital, University of California San Francisco, England's National Health Service and Qure.ai. Read more » DispatchHealth Looks To Expand In-home Care With More Than $330M in Financing By Marissa Plescia Tuesday, November 29, 2022 5:34 PM The funding round was led by Optum Ventures. Other investors include Adams Street Partners, Blue Shield of California and Humana. DispatchHealth will use the money to expand its capabilities in current markets, its CEO said. Read more » A multifaceted approach to improve cancer treatment and care By Valeria Fantin Tuesday, November 29, 2022 4:51 PM We now see the next wave of potential cancer therapies on the horizon, propelled by significant advancements in immunology, as well as an increased understanding of tumor-driven mechanisms of immune evasion. Read more » A Dose of Innovation By Marina Record Tuesday, November 29, 2022 4:27 PM As gene sequencing, machine learning, powerful imaging, sensors, gene and cell therapies make their way out of academic labs into everyday healthcare, our approach to healthcare is changing. For the first time, not only can we pinpoint the molecular and genetic causes of disease, but we also have the technologies to access them. On the back of this, prevention and cures are becoming possible. Can we afford them? Read more » Report: Average Monthly Premiums for MA Plans Up First Time in 4 Years By Marissa Plescia Tuesday, November 29, 2022 4:12 PM The average monthly premium for Medicare Advantage plans increased to $7 in the first half of the Medicare Annual Open Enrollment period this year, the eHealth report found. Premiums were in the $4 to $5 range for the last three years. Read more » 2 Changes Siddhartha Mukherjee Is Calling for in Cancer Care By Katie Adams Tuesday, November 29, 2022 1:38 PM If the medical field wants to make serious progress on the Cancer Moonshot effort, it must expand its definition of personalized medicine and explore fresh approaches to cancer prevention, according to Dr. Siddhartha Mukherjee, a Pulitzer Prize-winning author and cancer physician at Columbia University Medical Center. Read more » Roche Withdraws Immunotherapy in U.S. for Bladder Cancer After Failed Study By Frank Vinluan Tuesday, November 29, 2022 12:28 PM Tecentriq failed to beat chemotherapy in improving overall survival, the main goal of its confirmatory Phase 3 test in bladder cancer. The drug had been granted accelerated approval based on results from a single-arm Phase 2 clinical trial. Read more » SPONSORED 6 Highlights from HLTH 2022 Among the takeaways from HLTH 2022 were the impact of consolidation on clinicians, behavioral health tools to help consumers manage stress and anxiety more productively, and how health tech and medtech companies are supporting remote patient monitoring and testing.   MedCity News   611 Broadway    New York,  NY   10012   United States You received this email because you are subscribed to MedCity Daily Digest from MedCity News. Update your email preferences to choose the types of emails you receive.  Unsubscribe from all future emails